Podium to Practice: ASH® 2025 – LEUKEMIA: AUGMENT-101 Study

Podium to Practice: ASH® 2025 – LEUKEMIA: AUGMENT-101 Study

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Jorge Cortes

Icon Chair Speaker

Speakers

Dr. Lynn Savoie

Dr. Brian Leber

Studies / Trials Discussed

ID 1001 – Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

This program has been made possible through unrestricted support from Astellas and Daiichi Sankyo.

Studies/trials discussed:

ID 1001 – Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study
Tagged